As biosimilars enter the U.S. marketplace, health-system pharmacists will be asked to take prudent measures as they consider and evaluate these therapies for substitution into their formularies. Pharmacists can seize the intervening time to assume leadership positions in preparing their organizations and clinical colleagues for the continued development of this new product class. Additionally, they can ensure that an appropriate clinical infrastructure will be in place to allow for the safe and effective prescribing, administration, and monitoring of biosimilars. This monograph provides an update on the introduction of biosimilars in the United States, FDA draft guidance documents, state legislative activity regarding substitutability, and issues related to biosimilar naming and interchangeability with reference products.
Populaire auteurs
Cram101 Textbook Reviews (948) J.S. Bach (447) Wolfgang Amadeus Mozart (305) Collectif (268) Schrijf als eerste een recensie over dit item (259) Doug Gelbert (238) Princess of Patterns (211) Charles Dickens (209) R.B. Grimm (197) Carolyn Keene (187) Jules Verne (183) Philipp Winterberg (180) William Shakespeare (174) Youscribe (172) Lucas Nicolato (169) Edgar Allan Poe (166) Herman Melville (166) Anonymous (165) Gilad Soffer (164) Robert Louis Stevenson (159)Populaire gewichtsboeken
418 KB 425 KB 435 KB 459 KB 445 KB 439 KB 386 KB 413 KB 493 KB 432 KB 455 KB 471 KB 421 KB 451 KB 485 KB 472 KB 416 KB 369 KB 419 KB 427 KB